Ombitasvir
Based on 9 publication(s) in Google Scholar
Ombitasvir is a potent inhibitor of the hepatitis C virus protein NS5A, with EC50s of 0.82 to 19.3 pM against HCV genotypes 1 to 5, and 366 pM against genotype 6a.
For research use only. We do not sell to patients.
- Purity: 98.62%
- CAS No.: 1258226-87-7
- Formula: C50H67N7O8
- Molecular Weight:894.11
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
FDA-Approved Drug Library
HY-L022
-
Antiviral Compound Library
HY-L027
-
Drug Repurposing Compound Library
HY-L035
-
NMPA-Approved Drug Library
HY-L053
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Anti-Hepatitis C Virus Compound Library
HY-L073
-
Targeted Diversity Library
HY-L099
-
EMA-Approved Drug Library
HY-L116
-
Human Metabolite Library
HY-L123
-
Withdrawn Drug Compound Library
HY-L140
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
Publications Citing Use of MedChemExpress (MCE) Ombitasvir
More- Int J Mol Sci. 2025 Feb 6;26(3):1381. [Abstract]
- Antiviral Res. 2017 Mar;139:18-24. [Abstract]
- J Virol. 2018 Jan 2;92(2). pii: e01582-17. [Abstract]
- J Liq ChromaTogr R T. 2019: 1-9.
- Xenobiotica. 2019 Aug;49(8):935-944. [Abstract]
- University of Glasgow. 2024 Mar.
- SSRN. 2024 Jan 26.
- Chemrxiv. 2021, Jun 10.
- Chem Cent J. 2017 Jan 3:11:1. [Abstract]
Biological Activity
EC50: 0.82 to 19.3 pM (HCV genotypes 1 to 5), 366 pM (HCV genotype 6a)[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Huh-7 | CC50 |
>1 nM
Compound: Ombitasvir
|
Cytotoxicity against human HuH7 replicon cells after 3 days by CellTiter-Fluor assay
Cytotoxicity against human HuH7 replicon cells after 3 days by CellTiter-Fluor assay
|
[PMID: 29454920] |
| Huh-7 | EC50 |
0.005 nM
Compound: 38, ABT-267
|
Antiviral activity against HCV1b Con1 infected in human HuH7 cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene assay
Antiviral activity against HCV1b Con1 infected in human HuH7 cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene assay
|
[PMID: 24400777] |
| Huh-7 | EC50 |
0.014 nM
Compound: 38, ABT-267
|
Antiviral activity against HCV1a H77 infected in human HuH7 cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene assay
Antiviral activity against HCV1a H77 infected in human HuH7 cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene assay
|
[PMID: 24400777] |
| Huh-7 | EC50 |
0.056 nM
Compound: 38, ABT-267
|
Antiviral activity against HCV1b Con1 infected in human HuH7 cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene assay in presence of 40% human plasma
Antiviral activity against HCV1b Con1 infected in human HuH7 cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene assay in presence of 40% human plasma
|
[PMID: 24400777] |
| Huh-7 | EC50 |
0.186 nM
Compound: 38, ABT-267
|
Antiviral activity against HCV1a H77 infected in human HuH7 cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene assay in presence of 40% human plasma
Antiviral activity against HCV1a H77 infected in human HuH7 cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene assay in presence of 40% human plasma
|
[PMID: 24400777] |
| Huh-7 | EC50 |
1.71 pM
Compound: 38, ABT-267
|
Antiviral activity against HCV4a infected in human HuH7 cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene assay
Antiviral activity against HCV4a infected in human HuH7 cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene assay
|
[PMID: 24400777] |
| Huh-7 | EC50 |
12.4 pM
Compound: 38, ABT-267
|
Antiviral activity against HCV2a infected in human HuH7 cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene assay
Antiviral activity against HCV2a infected in human HuH7 cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene assay
|
[PMID: 24400777] |
| Huh-7 | EC50 |
19.3 pM
Compound: 38, ABT-267
|
Antiviral activity against HCV3a infected in human HuH7 cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene assay
Antiviral activity against HCV3a infected in human HuH7 cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene assay
|
[PMID: 24400777] |
| Huh-7 | EC50 |
4.3 pM
Compound: 38, ABT-267
|
Antiviral activity against HCV2b infected in human HuH7 cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene assay
Antiviral activity against HCV2b infected in human HuH7 cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene assay
|
[PMID: 24400777] |
| Huh-7 | EC50 |
4.3 pM
Compound: 38, ABT-267
|
Antiviral activity against HCV5a infected in human HuH7 cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene assay
Antiviral activity against HCV5a infected in human HuH7 cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene assay
|
[PMID: 24400777] |
| Huh-7 | EC50 |
415 pM
Compound: 38, ABT-267
|
Antiviral activity against HCV6a infected in human HuH7 cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene assay
Antiviral activity against HCV6a infected in human HuH7 cells assessed as inhibition of viral replication after 4 days by luciferase reporter gene assay
|
[PMID: 24400777] |
Ombitasvir is active against the genotype 2a JFH-1 replicon, with an EC50 of 0.82 pM, and the EC50s of ombitasvir are 42 pM and 68 pM against the L28 and F28 variants of this genotype 6a replicon, respectively[1]. In GT1a, variants M28V, L31V, and H58D confers 58- to 243-fold resistance to Ombitasvir. Single variants M28T, Q30R, and Y93C/S confers 800- to 8965-fold resistance, while Y93H/N confers >40000-fold resistance to Ombitasvir[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1258226-87-7
-
Appearance Solid
-
Molecular Weight 894.11
-
Formula C50H67N7O8
-
Color White to light yellow
-
SMILES
CC(C)(C)C(C=C1)=CC=C1N2[C@H](C3=CC=C(NC([C@H]4N(C([C@@H](NC(OC)=O)C(C)C)=O)CCC4)=O)C=C3)CC[C@H]2C5=CC=C(NC([C@@H]6CCCN6C([C@@H](NC(OC)=O)C(C)C)=O)=O)C=C5
-
Synonyms
ABT-267
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (9)
-
Journal Impact Factor
-
Most Recent
-
Int J Mol Sci
Discovery of TRPV4-Targeting Small Molecules with Anti-Influenza Effects Through Machine Learning and Experimental Validation. [Abstract]2025 Feb 6;26(3):1381. PMID: 39941149 -
Antiviral Res
A profiling study of a newly developed HCVcc strain PR63cc's sensitivity to direct-acting antivirals. [Abstract]2017 Mar;139:18-24. PMID: 28025084 -
J Virol
2018 Jan 2;92(2). pii: e01582-17. PMID: 29093094 -
-
Xenobiotica
Minor contribution of CYP3A5 to the metabolism of hepatitis C protease inhibitor paritaprevir in vitro. [Abstract]2019 Aug;49(8):935-944. PMID: 30227770 -
-
-
-
Chem Cent J
Simultaneous determination of newly developed antiviral agents in pharmaceutical formulations by HPLC-DAD. [Abstract]2017 Jan 3:11:1. PMID: 28101128
Solvent & Solubility
DMSO : ≥ 33 mg/mL (36.91 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (2.80 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (274 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Krishnan P, et al. In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A. Antimicrob Agents Chemother. 2015 Feb;59(2):979-87 [Content Brief]
[2]. DeGoey DA, et al. Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A. J Med Chem. 2014 Mar 13;57(5):2047-57 [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.1184 mL | 5.5922 mL | 11.1843 mL | 27.9608 mL |
| 5 mM | 0.2237 mL | 1.1184 mL | 2.2369 mL | 5.5922 mL | |
| 10 mM | 0.1118 mL | 0.5592 mL | 1.1184 mL | 2.7961 mL | |
| 15 mM | 0.0746 mL | 0.3728 mL | 0.7456 mL | 1.8641 mL | |
| 20 mM | 0.0559 mL | 0.2796 mL | 0.5592 mL | 1.3980 mL | |
| 25 mM | 0.0447 mL | 0.2237 mL | 0.4474 mL | 1.1184 mL | |
| 30 mM | 0.0373 mL | 0.1864 mL | 0.3728 mL | 0.9320 mL |
Powered by Bioz